Showing 1,681 - 1,700 results of 21,342 for search '(( significantly ((less decrease) OR (treatment decreased)) ) OR ( significant decrease decrease ))', query time: 0.65s Refine Results
  1. 1681
  2. 1682
  3. 1683
  4. 1684

    S1 Data - by Jia Long (288557)

    Published 2024
    “…The total chlorophyll content of blueberry leaves at 25% light intensity increased by 76.4% compared with CK during the blue fruiting stage; the maximum net photosynthetic rate (Pmax), light compensation point (LCP), light saturation point (LSP), rate of dark respirations (Rd), inter-cellular CO<sub>2</sub> concentration (Ci), stomatal conductance (Gs), transpiration rate (Tr), net photosynthesis rate (Pn), and chlorophyll a/b showed a decreasing trend with decreasing light intensity. The Pn of blueberry leaves was highest under full light conditions at all three stages, and the Pn at 25% light intensity decreased by 68.5% compared with CK during the white fruiting stage Reflecting the fact that blueberries can adapt to low-light environments through increases in chlorophyll and carotenoids, but reduced light intensity significantly inhibited their photosynthesis. …”
  5. 1685

    Number of visits per clinic type, 2013-2015. by Jacob Dreiher (14856863)

    Published 2025
    “…During PE, statistically significant longer waiting times were found for surgery (+1.0 day) and imaging (+1.1 days), while a 2.4 days decrease was noted in pediatrics, controlled for age, sex, ethnicity and the daily number of visits. …”
  6. 1686
  7. 1687
  8. 1688
  9. 1689
  10. 1690

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  11. 1691

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  12. 1692

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  13. 1693
  14. 1694
  15. 1695
  16. 1696
  17. 1697
  18. 1698
  19. 1699
  20. 1700